This post may contain affiliate links which may compensate us based on your interaction. Please read the disclosures for more information.
A major telehealth split could reshape how millions access — and afford — popular weight-loss drugs.
The weight-loss drug market just got more complicated. Novo Nordisk announced it is cutting ties with telehealth giant Hims & Hers Health, pulling its blockbuster drug Wegovy from the platform after accusing the company of selling “illegitimate, knockoff versions” that could put patients at risk, according to CBS News. This breakup matters for anyone considering these increasingly popular…
